Phaseline

Companies › Andover Research Eye Institute

Andover Research Eye Institute: clinical trials, targets and expected readouts

2 active drug programs in 2 registered trials: 2 Phase 4; Ophthalmology; next expected readout Dec 2026.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
Preservative Free Polyethylene glycol 400 0.25%–Phase 4Dry Eye Disease (DED)Dec 2026
Propylene Glycol–Phase 4Dry Eye Disease (DED)Dec 2026

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT07676084Preservative Free Polyethylene glycol 400 0.25%Phase 4Dry Eye Disease (DED)OphthalmologyDec 2026
NCT07676084Propylene GlycolPhase 4Dry Eye Disease (DED)OphthalmologyDec 2026

Targets

No annotated target.

Companies with the same targets

–

Companies built like this

SANGMYUNG innovation Cloudbreak Therapeutics Omikron Italia S.r.l. Viridian Therapeutics Aurion Biotech

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.